123 related articles for article (PubMed ID: 36470146)
1. Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events.
Zhang X; Yin X; Zhang L; Ye Z; Liang G
Comput Biol Med; 2023 Jan; 152():106346. PubMed ID: 36470146
[TBL] [Abstract][Full Text] [Related]
2. Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma.
Guo H; Wang S; Xie A; Sun W; Wei C; Xian S; Yin H; Li M; Sun H; Li H; Meng T; Zhang J; Huang Z
Dis Markers; 2021; 2021():1484227. PubMed ID: 34745385
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
5. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
6. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
[TBL] [Abstract][Full Text] [Related]
7. Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas.
Yang L; He Y; Zhang Z; Wang W
PeerJ; 2019; 7():e8245. PubMed ID: 31844595
[TBL] [Abstract][Full Text] [Related]
8. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
Zhang D; Zou D; Deng Y; Yang L
J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
[TBL] [Abstract][Full Text] [Related]
9. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
Liu Y; Jia W; Li J; Zhu H; Yu J
Front Oncol; 2020; 10():587343. PubMed ID: 33117720
[No Abstract] [Full Text] [Related]
10. The systematic identification of survival-related alternative splicing events and splicing factors in glioblastoma.
Peng T; Liu Z; Zhang Y; Liu X; Zhao L; Ma Y; Fan J; Song X; Wang L
Ann Hum Genet; 2024 Feb; ():. PubMed ID: 38369937
[TBL] [Abstract][Full Text] [Related]
11. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma.
Jiang Y; Zhang C; Chen Y; Zhao S; He Y; He J
Cancer Med; 2023 Feb; 12(4):4895-4906. PubMed ID: 36031798
[TBL] [Abstract][Full Text] [Related]
12. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
13. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data.
Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS
Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810
[TBL] [Abstract][Full Text] [Related]
14. Systematic Identification of Survival-Associated Alternative Splicing Events in Kidney Renal Clear Cell Carcinoma.
Wei Y; Zhang Z; Peng R; Sun Y; Zhang L; Liu H
Comput Math Methods Med; 2021; 2021():5576933. PubMed ID: 33959190
[TBL] [Abstract][Full Text] [Related]
15. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
17. The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer.
Wu S; Wang J; Zhu X; Chyr J; Zhou X; Wu X; Huang L
Front Genet; 2020; 11():604262. PubMed ID: 33519909
[TBL] [Abstract][Full Text] [Related]
18. Identification of Ferroptosis-Related Gene Prognostic Signature and HSF1 for Reversing Doxorubicin and Gemcitabine Resistance in Uterine Carcinosarcoma.
Han S; Liu Q; Yang Z; Ma J; Liu D; Yan C; Liang D
Dis Markers; 2022; 2022():6400227. PubMed ID: 35069934
[TBL] [Abstract][Full Text] [Related]
19. Identification of an alternative splicing signature as an independent factor in colon cancer.
Chen H; Luo J; Guo J
BMC Cancer; 2020 Sep; 20(1):904. PubMed ID: 32962686
[TBL] [Abstract][Full Text] [Related]
20. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
